CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 2, 2009, Pages 126-136

  Verhofstede, Chris ^a,d   Vandekerckhove, Linos ^b   Van Eygen, Veerle ^c   Demecheleer, Els ^a   Vandenbroucke, Ina ^c   Winters, Bart ^c   Plum, Jean ^a   Vogelaers, Dirk ^b   Stuyver, Lieven ^c  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Virco BVBA   (Belgium)

^d AIDS Reference Laboratory   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DNA; GLYCOPROTEIN GP 120; LAMIVUDINE; RNA; ZALCITABINE; ZIDOVUDINE; VIRUS DNA; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA SEQUENCE; VIRUS ENVELOPE; VIRUS LOAD; VIRUS TYPING; BLOOD; CHEMISTRY; CLASSIFICATION; GENETIC VARIABILITY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MONONUCLEAR CELL; PLASMA; VIROLOGY;

ADULT; CLONING, MOLECULAR; DNA, VIRAL; GENETIC VARIATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLASMA; RECEPTORS, CXCR4; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 60749113438     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819118fa     Document Type: Article

References (45)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Anna Rev Immunol. 1999;17:657-700.
2. Asjo B, Albert J, Karlsson A, et al. Replicative capacity of human-immunodeficiency-virus from patients with varying severity of HIV-infection. Lancet. 1986;2:660-662.
3. Fenyo EM, Morfeldtmanson L, Chiodi F, et al. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol. 1988;62:4414-4419.
4. Evans LA, Mchugh TM, Stiles DP, et al. Differential ability of human-immunodeficiency-virus isolates to productively infect human-cells. J Immunol. 1987;138:3415-3418.
5. Chengmayer C, Seto D, Tateno M, et al. Biologic features of HIV-1 that correlate with virulence in the host. Science. 1988;240:80-82.
6. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621-628.
7. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human-immunodeficiency-virus on disease progression. J Infect Dis. 1994;169:968-974.
8. Schramm B, Penn ML, Speck RF, et al. Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease. J Virol. 2000;74:184-192.
9. Van Baelen K, Vandenbroucke I, Rondelez E, et al. HIV-1 coreceptor usage determination in clinical isolates using clonal and population-based genotypic and phenotypic assays. J Virol Methods. 2007;146:61-73.
10. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51:566-575.
11. Trouplin V, Salvatori F, Cappello F, et al. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol. 2001;75:251-259.
12. Jensen MA, Li FS, van't Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol. 2003;77:13376-13388.
13. Sing T, Low AJ, Beerenwinkel N, et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther. 2007;12:1097-1106.
14. Pillai S, Good B, Richman D, et al. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses. 2003;19:145-149.
15. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, et al. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol. 2002;76:3852-3864.
16. Low AJ, Dong W, Chan D, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS. 2007;21:F19-F26.
17. Delobel P, Nugeyre MT, Cazabat M, et al. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol. 2007;45:1572-1580.
18. Poveda E, Briz V, Roulet V, et al. Correlation between a phenotypic assay and three bioinformatic tools for determining HFV co-receptor use. AIDS. 2007;21:1487-1490.
19. Vandenbroucke I, Van Eygen V, Rondelez E, et al. Detection limit of X4 minority virus in abundant R5-tropic virus populations in standard genotypic and phenotypic assays. Antivir Ther. 2007;12:S154.
20. Nielsen C, Petersen JL, Nielsen CM, et al. Isolation of HIV using lymphocyte-T panning-methodological aspects. J Virol Methods. 1989;26:105-114.
21. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985;229:563-566.
22. Tamura K, Dudley J, Nei M, et al. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596-1599.
23. Garrido C, Roulet y Chueca N, et al. Evaluation of seven different bioinformatic tools to predict HIV-1 tropism in non-B sub-types and concordance with a phenotypic assay. Antivir Ther. 2007;12:8161.
24. van Rij RP, Visser JA, van Praag RME, et al. Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs. J Virol. 2002;76:3054-3058.
25. Pierson T, Hoffman TL, Blankson J, et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol. 2000;74:7824-7833.
26. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HFV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2005;38:382-392.
27. Izopet J, Cazabat M, Pasquier C, et al. Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. Virology. 2002;302:393-404.
28. Smith MS, Koerber KL, Pagano JS. Zidovudine-resistant human-immunodeficiency-virus type-1 genomes detected in plasma distinct from viral genomes in peripheral-blood mononuclear-cells. J Infect Dis. 1993;167:445-448.
29. Kaye S, Comber E, Tenantflowers M, et al. The appearance of drug resistance-associated point mutations in HIV type-1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses. 1995;11:1221-1225.
30. Fenyo EM, Albert J, Asjo B. Replicative capacity, cytopathic effect and cell tropism of HIV AIDS. 1989;3:S5-S12.
31. van Rij RP, Blaak H, Visser JA, et al. Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. J Clin Invest. 2000;106:1569.
32. Lee B, Sharron M, Tsang M, et al. Quantification of CD4, CCR5, CXCR4, and STRL33 levels on differentially conditioned monocyte-derived macrophages, various subsets of peripheral blood leukocytes and CD34+ bone marrow progenitor cells. Blood. 1998;92:164a.
33. Grivel JC, Elliott J, Lisco A, et al. HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5-and CXCR4-tropic HIV-1. AIDS. 2007;21:1263-1272.
34. Pantaleo G, Graziosi C, Butini L, et al. Lymphoid organs function as major reservoirs for human-immunodeficiency-virus. Proc Natl Acad Sci USA. 1991;88:9838-9842.
35. Pantaleo G, Graziosi C, Demarest JF, et al. HIV-infection is active and progressive during the prolonged period of clinical latency. J Immunol. 1993;150:A243.
36. Schweighardt B, Roy AM, Meiklejohn DA, et al. R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4(+) T-cell cultures than X4 HIV-1. J Virol. 2004;78:9164-9173.
37. Bouhabib DC, Roderiquez G, Oravecz T, et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human-immunodeficiency-virus type-1 from antibody neutralization. J Virol. 1994;68:6006-6013.
38. Chengmayer C, Homsy J, Evans LA, et al. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci USA. 1988;85:2815-2819.
39. Callaway DS, Ribeiro RM, Nowak MA. Virus phenotype switching and disease progression in HIV-1 infection. Proc R Soc Land B Biol Sci. 1999;266:2523-2530.
40. Cornelissen M, Mulderkampinga G, Veenstra J, et al. Syncytium-inducing (Si) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/Si phenotypically mixed human-immunodeficiency-virus population. J Virol. 1995;69:1810-1818.
41. Bunnik EM, Quakkelaar ED, van Nuenen AC, et al. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient. J Virol. 2007;81:525-531.
42. Wout ABVT, Ran LJ, Nijhuis M, et al. Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo. AIDS. 1998;12:1169-1176.
43. Delforge ML, Liesnard C, Debaisieux L, et al. In-vivo inhibition of syncytium-inducing variants of HFV in patients treated with didanosine. AIDS. 1995;9:89-90.
44. vantWout AB, Ran LJ, deJong MD, et al. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J Clin Invest. 1997;100:2325-2332.
45. Angarano G, Monno L, Vivirito MC, et al. The role of HIV type 1 phenotype and genotype in long-term responders to zidovudine therapy. AIDS Res Hum Retroviruses. 1996;12:969-975.